Trial: 202009151

A Phase 1 Dose Escalation and Cohort Expansion Study of the Safety and Efficacy of Anti-CD19 Allogeneic CRISPR-Cas9Engineered T Cells (CTX110) in Subjects With Relapsed or Refractory B Cell Malignancies


I (Cancer Control)

Principal Investigator

Ghobadi, Armin

Disease Site

Lymphoid Leukemia; Non-Hodgkin Lymphoma

Learn more about this study at: